| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Actual experience and future development of gemcitabine in superficial bladder cancer
|
Gontero, P.
|
|
|
17 |
S5 |
p. v123-v128
|
article
|
| 2 |
Adjuvant chemotherapy of bladder cancer
|
Boccardo, F.
|
|
|
17 |
S5 |
p. v129-v132
|
article
|
| 3 |
A phase II study of Gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature
|
Zustovich, F.
|
|
|
17 |
S5 |
p. v133-v136
|
article
|
| 4 |
Biological agents and gemcitabine in the treatment of breast cancer
|
Morandi, P.
|
|
|
17 |
S5 |
p. v177-v180
|
article
|
| 5 |
Cellular pharmacology of gemcitabine
|
Mini, E.
|
|
|
17 |
S5 |
p. v7-v12
|
article
|
| 6 |
Challenges for chemotherapy in ovarian cancer
|
Ozols, R.F.
|
|
|
17 |
S5 |
p. v181-v187
|
article
|
| 7 |
Challenges in the treatment of bladder cancer
|
Kaufman, D.S.
|
|
|
17 |
S5 |
p. v106-v112
|
article
|
| 8 |
Challenges in the treatment of gastrointestinal tumours
|
Labianca, R.
|
|
|
17 |
S5 |
p. v137-v141
|
article
|
| 9 |
Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine
|
Trodella, L.
|
|
|
17 |
S5 |
p. v52-v54
|
article
|
| 10 |
Chemotherapy advances in small cell lung cancer
|
Rosti, G.
|
|
|
17 |
S5 |
p. v99-v102
|
article
|
| 11 |
Chemotherapy of advanced NSCLC in special patient population
|
Gridelli, C.
|
|
|
17 |
S5 |
p. v72-v78
|
article
|
| 12 |
Clinical studies of pemetrexed and gemcitabine combinations
|
Adjei, A.A.
|
|
|
17 |
S5 |
p. v29-v32
|
article
|
| 13 |
Current status of adjuvant chemotherapy in NSCLC
|
Scagliotti, G.V.
|
|
|
17 |
S5 |
p. v62-v63
|
article
|
| 14 |
Development of gemcitabine in non-small cell lung cancer: the Italian contribution
|
Metro, G.
|
|
|
17 |
S5 |
p. v37-v46
|
article
|
| 15 |
First line chemotherapy in advanced or metastatic NSCLC
|
Rinaldi, M.
|
|
|
17 |
S5 |
p. v64-v67
|
article
|
| 16 |
First line chemotherapy of metastatic breast cancer
|
Pronzato, P.
|
|
|
17 |
S5 |
p. v165-v168
|
article
|
| 17 |
Gemcitabine and anthracyclines in platinum-resistant ovarian cancer
|
Galligioni, E.
|
|
|
17 |
S5 |
p. v195-v198
|
article
|
| 18 |
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature
|
Pastorelli, D.
|
|
|
17 |
S5 |
p. v153-v157
|
article
|
| 19 |
Gemcitabine and taxanes in metastatic breast cancer
|
Amadori, D.
|
|
|
17 |
S5 |
p. v173-v176
|
article
|
| 20 |
Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium
|
Bellmunt, J.
|
|
|
17 |
S5 |
p. v113-v117
|
article
|
| 21 |
Gemcitabine: monochemotherapy of breast cancer
|
Ferrazzi, E.
|
|
|
17 |
S5 |
p. v169-v172
|
article
|
| 22 |
Guest Editors
|
Cartei, G.
|
|
|
17 |
S5 |
p. v1-v2
|
article
|
| 23 |
Introduction
|
Cartei, G.
|
|
|
17 |
S5 |
p. v5-v6
|
article
|
| 24 |
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer
|
Richter, S.N.
|
|
|
17 |
S5 |
p. v20-v24
|
article
|
| 25 |
In vitro studies on gemcitabine combinations with other antiblastics
|
Giovannetti, E.
|
|
|
17 |
S5 |
p. v17-v19
|
article
|
| 26 |
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer
|
Roberts, J.T.
|
|
|
17 |
S5 |
p. v118-v122
|
article
|
| 27 |
Multimodal approach to ovarian cancer
|
Scarfone, G.
|
|
|
17 |
S5 |
p. v199-v200
|
article
|
| 28 |
Neo-adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
|
Santo, A.
|
|
|
17 |
S5 |
p. v55-v61
|
article
|
| 29 |
New target therapies in advanced pancreatic cancer
|
Cascinu, S.
|
|
|
17 |
S5 |
p. v148-v152
|
article
|
| 30 |
Non-platinum combination of gemcitabine in NSCLC
|
Favaretto, A.G.
|
|
|
17 |
S5 |
p. v82-v85
|
article
|
| 31 |
Non-small-cell lung cancer: which platinum for gemcitabine?
|
Boni, C.
|
|
|
17 |
S5 |
p. v79-v81
|
article
|
| 32 |
Novel targeted approaches in non-small cell lung cancer (NSCLC)
|
Ardizzoni, A.
|
|
|
17 |
S5 |
p. v91-v93
|
article
|
| 33 |
Pemetrexed and malignant pleural mesothelioma
|
Marangolo, M.
|
|
|
17 |
S5 |
p. v103-v105
|
article
|
| 34 |
Pharmacogenomics and gemcitabine
|
Rosell, R.
|
|
|
17 |
S5 |
p. v13-v16
|
article
|
| 35 |
Pharmacokinetic evaluation of gemcitabine and 2′,2′-difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors
|
Cattel, L.
|
|
|
17 |
S5 |
p. v142-v147
|
article
|
| 36 |
Primary systemic therapy in operable breast cancer: clinical data and biological fall-out
|
Maur, M.
|
|
|
17 |
S5 |
p. v158-v164
|
article
|
| 37 |
Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer
|
Monnerat, C.
|
|
|
17 |
S5 |
p. v86-v90
|
article
|
| 38 |
Role of gemcitabine in ovarian cancer treatment
|
Lorusso, D.
|
|
|
17 |
S5 |
p. v188-v194
|
article
|
| 39 |
Second-line chemotherapy for non-small cell lung cancer
|
De Marinis, F.
|
|
|
17 |
S5 |
p. v68-v71
|
article
|
| 40 |
Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy
|
Cartei, G.
|
|
|
17 |
S5 |
p. v47-v51
|
article
|
| 41 |
Table of Contents
|
|
|
|
17 |
S5 |
p. iv-v
|
article
|
| 42 |
The surgeon and the oncologist in non-small cell lung cancer (NSCLC)
|
Sartori, F.
|
|
|
17 |
S5 |
p. v94-v98
|
article
|
| 43 |
Topoisomerase I, IIα and IIβ mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results
|
Cartei, G.
|
|
|
17 |
S5 |
p. v25-v28
|
article
|
| 44 |
10-year update on chemotherapy for non-small cell lung cancer
|
Abratt, R.P.
|
|
|
17 |
S5 |
p. v33-v36
|
article
|
Journal description